Charles S. Berkman

2012 - Ligand Pharmaceuticals

In 2012, Charles S. Berkman earned a total compensation of $685.2K as Vice President and General Counsel at Ligand Pharmaceuticals, a 43% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$110,081
Option Awards$223,118
Salary$275,202
Stock Awards$72,350
Other$4,455
Total$685,206

Berkman received $275.2K in salary, accounting for 40% of the total pay in 2012.

Berkman also received $110.1K in non-equity incentive plan, $223.1K in option awards, $72.4K in stock awards and $4.5K in other compensation.

Rankings

In 2012, Charles S. Berkman's compensation ranked 7,641st out of 11,487 executives tracked by ExecPay. In other words, Berkman earned more than 33.5% of executives.

ClassificationRankingPercentile
All
7,641
out of 11,487
34th
Division
Manufacturing
2,748
out of 4,253
35th
Major group
Chemicals And Allied Products
717
out of 1,198
40th
Industry group
Drugs
505
out of 920
45th
Industry
Pharmaceutical Preparations
397
out of 700
43rd
Source: SEC filing on March 12, 2015.

Berkman's colleagues

We found four more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2012.

2012

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2012

Nishan de Silva

Ligand Pharmaceuticals

Chief Financial Officer

2012

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2012

John Sharp

Ligand Pharmaceuticals

Chief Financial Officer

News

You may also like